https://newshealth.biz/health-news/adjuvant-belzutifan-pembrolizumab-significantly-boosts-dfs-in-kidney-cancer/
Adjuvant Belzutifan-Pembrolizumab Significantly Boosts DFS in Kidney Cancer | News Health
Feb 28, 2026 - (MedPage Today) -- SAN FRANCISCO -- The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease-free survival
kidney cancer newsadjuvantpembrolizumabsignificantlyboosts